Exozymes (EXOZ) Receivables - Other (2024 - 2026)
Exozymes (EXOZ) posted quarterly Receivables - Other of $5330.0 for Q4 2025, down 97.02% year-over-year from $178966.0 in Q4 2024, and down 68.8% quarter-over-quarter from $17085.0 in Q3 2025.
Exozymes (EXOZ) Receivables - Other (2024 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Receivables - Other for 2 consecutive years, with $5330.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Other fell 97.02% year-over-year to $5330.0; the TTM figure through Dec 2025 stood at $5330.0 (down 97.02% YoY), while the FY2025 annual figure was $5330.0, down 97.02% from the prior year.
- Receivables - Other slipped to $5330.0 in Q4 2025 per EXOZ's latest filing, from $17085.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $178966.0 in Q4 2024 and bottomed at $346.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - |
| 10 | Exozymes | 61.57 Mn | 61.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18,616.00 |
| Jun 30, 2026 | 18,616.00 |
| Dec 31, 2025 | 5,330.00 |
| Dec 31, 2025 | 5,330.00 |
| Sep 30, 2025 | 17,085.00 |
| Sep 30, 2025 | 17,085.00 |
| Jun 30, 2025 | 346.00 |
| Jun 30, 2025 | 346.00 |
| Dec 31, 2024 | 178,966.00 |
| Dec 31, 2024 | 178,966.00 |